Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Hepatitis C Patient Management and Family Health Education

19. januar 2019 oppdatert av: China Liver Health

Health Education Based on We Media to Promote Patient Adherence to HCV Treatment: A Nationwide Online Randomized Controlled Trial

INTRODUCTION: Hepatitis C virus (HCV) is recognized as the leading cause of chronic liver disease worldwide. However, the screening rate and treatment rate of HCV-infected patients in China is low, which increases the burden of patients and the infection risk of their family members. WeChat, an instant messaging software, is used in a very high proportion in China. Health promotion based on WeChat public platform is a very convenient and effective way of health education. Therefore, this study plans to apply WeChat to conduct health intervention for HCV-infected patients. The objective is to explore the effect of We-media-based health promotion method on the detection rate and treatment rate of HCV-infected and their family members.

METHOD: Recruitment will be conduct in 10 hospitals in Jilin, Beijing, Henan and Anhui provinces. The subjects should be patients new diagnosed with hepatitis C at the hospital and aged 18 to 69. After signing the consent form, eligible participants were selected through the inclusion and exclusion criteria. 1000 participants will be recruited for the trial. After completing an baseline reseach by a online questionnaire, patients will be randomly assigned to receive a targeted short article on HCV weekly or a general health article with no mention of HCV. The intervention will last three months and a follow-up will be conduct at three month after the last intervention.

OUTCOMES: The primary outcome is antiviral therapy. The secondary outcomes are cognition and attitude towards hepatitis C, factors influencing antiviral therapy, time to first treatment and the compliance of treatment.

Studieoversikt

Studietype

Intervensjonell

Registrering (Forventet)

1000

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 69 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Permanent residents in the province
  • Ages 18-69 (inclusive)
  • Both blood anti-HCV test and HCV-RNA test is positive
  • Familiar with the use of mobile phones and WeChat
  • Informed consent and voluntary participation in the study

Exclusion Criteria:

  • Temporary staff who come to the city to work, travel or visit relatives, or those who will be living in other cities for a long time
  • Suffering from other serious diseases
  • Patients with mental disorder or memory disorder
  • Pregnant women or those who have a plan to prepare for pregnancy within one year
  • Refuse to participate in the investigation

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Annen
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: intervensjonsgruppe
The intervention group receive a targeted short article on HCV from WeChat weekly.
Annen: kontrollgruppe
The control group receive a general health article with no mention of HCV from WeChat weekly.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Rate of antiviral therapy
Tidsramme: 6 months after the first intervention
The rate of antiviral therapy is equal to the number of subjects received antiviral therapy divide by the number of all subjects.
6 months after the first intervention

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Time to first treatment
Tidsramme: 6 months after the first intervention
This is the interval time between the first intervention and first treatment. We want to know from this outcome how long it takes the subject to receive the health intervention before starting treatment. Thus, we can analyze the relationship between intervention time and treatment behavior.
6 months after the first intervention
Cognition and attitude towards hepatitis C
Tidsramme: 6 months after the first intervention
Investigators designed a standardized questionnaire that asked questions about subjects' knowledge and attitudes toward hepatitis C. The scores of the questionnaire were used to evaluate the cognition and attitude of the subjects.
6 months after the first intervention
Factors influencing antiviral therapy
Tidsramme: 6 months after the first intervention
The investigators designed a ranking question of factors that interfered with the subjects' treatment in the questionnaire. These factors include: (1) My condition is not serious; (2) I am worried about the side effects of treatment; (3) I am afraid of being discriminated against because someone know I have the disease; (4) I have financial difficulties (or the treatment costs are too high); (5) The process of visiting a doctor is complicated. Subjects can also fill in their own ideas in the blank if they have other factors not mentioned in this questionnaire. Investigators will analyze the extent to which each factor affects a patient's treatment.
6 months after the first intervention
The rate of giving up treatment halfway
Tidsramme: 6 months after the first intervention
This rate is used to assess compliance with treatment. This rate is equal to the number of subjects who give up treatment halfway divided by the number of subjects who get treatment.
6 months after the first intervention

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Studieleder: Fuqiang Cui, PhD, Peking University
  • Hovedetterforsker: Tianshuo Zhao, Study Director
  • Hovedetterforsker: Yingsheng Shen, China Liver Health

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Forventet)

1. januar 2019

Primær fullføring (Forventet)

1. november 2019

Studiet fullført (Forventet)

1. november 2019

Datoer for studieregistrering

Først innsendt

18. januar 2019

Først innsendt som oppfylte QC-kriteriene

19. januar 2019

Først lagt ut (Faktiske)

23. januar 2019

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

23. januar 2019

Siste oppdatering sendt inn som oppfylte QC-kriteriene

19. januar 2019

Sist bekreftet

1. januar 2019

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere